Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;9(6):601-606.
doi: 10.21037/cdt.2019.07.03.

Shaping the future of renal denervation-the relevance of sham-controlled randomized trials and recent meta-analyses

Márcio G Kiuchi  1 , Jan K Ho  1 , Leslie Marisol Lugo Gavidia  1 , Markus P Schlaich  1   2   3
Affiliations
Editorial

Shaping the future of renal denervation-the relevance of sham-controlled randomized trials and recent meta-analyses

Márcio G Kiuchi et al. Cardiovasc Diagn Ther. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Markus P. Schlaich is supported by an NHMRC Research Fellowship and has received consulting fees, and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer-Ingelheim. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
24-h ambulatory systolic and diastolic blood pressure changes with RSD versus sham-controlled group. (A) Ambulatory systolic blood pressure (mmHg); (B) ambulatory diastolic blood pressure (mmHg). The size of central markers reflects the weight of each study. CI, confidence interval; IV, inverse variance; RADIANCE-HTN SOLO, a study of the ReCor medical paradise system in clinical hypertension; ReSET, renal sympathectomy in treatment resistant essential hypertension, a sham controlled randomized trial; RSD, renal sympathetic denervation; SPYRAL HTN-OFF MED, global clinical study of renal denervation with the Symplicity SpyralTM multi-electrode renal denervation system in patients with uncontrolled hypertension in the absence of antihypertensive medications; SPYRAL HTN-ON MED, global clinical study of renal denervation with the Symplicity SpyralTM multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy. With permission from (13).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959-68. 10.1001/jama.2013.184182 - DOI - PubMed
    1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23. 10.1016/S0140-6736(05)17741-1 - DOI - PubMed
    1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA 2017;317:165-82. 10.1001/jama.2016.19043 - DOI - PubMed
    1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81. 10.1016/S0140-6736(09)60566-3 - DOI - PubMed
    1. Symplicity HTN-2 Investigators , Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9. 10.1016/S0140-6736(10)62039-9 - DOI - PubMed